SBBPSwitched Batch Bernoulli Process
SBBPSouth Buda Business Park (Budapest, Hungary)
SBBPSeven Bladed Beta Propeller
SBBPSilly Bird Balloon Project (experiment; Germany)
SBBPSuper Brophy Brothers Podcast
SBBPSobotni Bielanski Bieg Poranny (Polish: Bielanski Saturday Morning Run; Poland)
SBBPShip Bottom Beach Patrol (Ship Bottom, NJ)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Stifel analyst Annabel Samimy acknowledged that Recorlev development timelines are pushed out by Strongbridge Biopharma (SBBP) expanding LOGICS to strengthen the clinical package.
and Canadian rights to Macrilen, the first and only FDA-approved oral growth hormone receptor indicated for the diagnosis of Adult Growth Hormone Deficiency, a rare endocrine disorder, from Strongbridge Biopharma (SBBP).
* Strongbridge Biopharma (NASDAQ: SBBP) shares hit a yearly low of $2.46.
Strongbridge Biopharma (SBBP) announced that the company has entered into an agreement for Novo Nordisk (NVO) to acquire the rights to MACRILEN in the United States and Canada.
* Strongbridge Biopharma plc (NASDAQ: SBBP) (before the market open)
In addition to Melinta, Johnson currently serves on the boards of Aveo Oncology (AVEO), Histogenics Corporation, Portola Pharmaceuticals (PTLA), and is chairman of Strongbridge Biopharma (SBBP).
Corcept Therapeutics (CORT) downgraded to Hold from Buy at Stifel with analyst Adam Walsh saying results are due near-term for both Strongbridge Biopharma's (SBBP) Recorlev and Novartis' (NVS) osilodrostat.